An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression

International Journal of Geriatric Psychiatry

Volumn 22, Issue 10, 2007, Pages 986-991

  Rutherford, Bret ^a,b   Sneed, Joel ^a   Miyazaki, Marissa ^a   Eisenstadt, Rachel ^a   Devanand, Devangere ^a   Sackeim, Harold ^a   Roose, Steven ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Aripiprazole; Augmentation; Geriatric depression; Open study; Remission; Selective serotonin reuptake inhibitor

Indexed keywords

ARIPIPRAZOLE; ESCITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADJUVANT THERAPY; ADULT; AGED; AGITATION; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; BLURRED VISION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; HAMILTON SCALE; HUMAN; HYPOTENSION; MAJOR DEPRESSION; MALE; MAXIMUM PERMISSIBLE DOSE; MINI MENTAL STATE EXAMINATION; NAUSEA; OPEN STUDY; OUTPATIENT; PATIENT COMPLIANCE; REMISSION; SIDE EFFECT; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 35448954915     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1775     Document Type: Article

References (14)

1. Alexopoulus GS, Streim JE, Carpenter D. 2004. Commentary: expert consensus guidelines for using antipsychotic agents in older patients. J Clin Psychiatry 65(Suppl 2): 100-102.
2. Baldwin RC, Simpson S. 1997. Prognosis and outcome studies in late life depression. Clin Neurosci 4: 16-22.
3. Georgotas A, McCue RE. 1989. The additional benefit of extending an antidepressant trial past seven weeks in the depressed elderly. Int J Geriatr Psych 4: 191-195.
4. Hamilton MW. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-60.
5. Hirose S, Ashby CR Jr. 2002. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 63: 733-736.
6. Lotrich FR, Pollock BG. 2005. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharm 45: 1105-1122.
7. Mulsant BH, Pollock BG. 1988. Treatment-resistant depression in late life. J Geriatr Psychiatry Neurol 11: 186-193.
8. Nemeroff CB, Gharabawi GM, Canuso CM, et al. 2004. Augmentation with risperidone in chronic resistant depression: a double-blind placebo-controlled maintenance trial. Neuropsychopharmacol 29: 5159.
9. Nemeroff CB. 2005. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 66(Suppl 8): 13-21.
10. Roose SP, Sackeim HA. 2004. Antidepressant medication for the treatment of late life depression. In Late Life Depression, Roose SP, Sackeim HA (eds). Oxford University Press: New York; 192-203.
11. Rush AJ, Trivedi MH, Wisniewski SR, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one of several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917.
12. Schneider LS, Tariot PN, Dagerman KS, et al. 2006. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New Engl J Med 355: 1525-1538.
13. Ventura J, Liberman RP, Green MF, et al. 1998. Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res 79: 163-173.
14. Zubenko GS, Mulsant BH, Sweet RA, et al. 1997. Mortality of elderly patients with psychiatric disorders. Am J Psychiatry 154: 1360-1368.